| Decision Aid to Support Advanced Cancer Patients (NCT04606238) | University Hospital Heidelberg | 2019-10-01 |
| Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer (NCT04121676) | Agenus Inc. | 2019-09-26 |
| Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) (NCT03980041) | Infinity Pharmaceuticals, Inc. | 2019-09-25 |
| Ketamine or Placebo in Patients With Major Depression and Advanced Cancer (NCT04471818) | Instituto Nacional de Cancerologia de Mexico | 2019-09-19 |
| Nutrition Assessment in Advanced Cancer Patients (NCT06323135) | West China Hospital | 2019-09-17 |
| An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers (NCT03994601) | Bristol-Myers Squibb | 2019-09-06 |
| A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors (NCT03954067) | Astellas Pharma Global Development, Inc. | 2019-09-03 |
| Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort (NCT03900442) | Prescient Therapeutics, Ltd. | 2019-09-01 |
| Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (NCT03909334) | Xiuning Le | 2019-07-25 |
| Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects (NCT04193319) | Jiangsu HengRui Medicine Co., Ltd. | 2019-07-19 |
| Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy (NCT03941262) | NKGen Biotech, Inc. | 2019-07-15 |
| Variation in Cancer Centers' End-of-Life Quality (NCT03780816) | Dartmouth-Hitchcock Medical Center | 2019-07-05 |
| Treatment of Carrying TP53 Harmful Mutations (NCT03645200) | Tianjin Medical University Second Hospital | 2019-07-01 |
| A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma (NCT03829254) | NuCana plc | 2019-06-17 |
| Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer (NCT03875781) | Assistance Publique - Hôpitaux de Paris | 2019-06-05 |
| Apatinib Plus SHR1210 in Advanced Mucosal Melanoma (NCT03986515) | Henan Cancer Hospital | 2019-06-04 |
| Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement (NCT06118125) | University of Bordeaux | 2019-06-01 |
| A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer (NCT03936959) | Eli Lilly and Company | 2019-05-24 |
| Crizotinib in ALK Rearranged Non-small-cell Lung Cancer (NCT04317651) | Fondazione Ricerca Traslazionale | 2019-05-16 |
| A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies (NCT03922204) | Merus B.V. | 2019-05-08 |
| Body Composition Manipulation in CoLorectal cancEr (BiCyCLE): Neuromuscular Electrical Stimulation (NMES) (NCT04065984) | London North West Healthcare NHS Trust | 2019-04-14 |
| An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors (NCT03745807) | Bristol-Myers Squibb | 2019-04-09 |
| Impact of a Resource-based Life Review Intervention on Advanced Cancer Patients (NCT04254926) | School of Health Sciences Geneva | 2019-04-06 |
| Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer (NCT03860272) | Agenus Inc. | 2019-03-20 |
| Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer (NCT03775525) | Genzada Pharmaceuticals USA, Inc. | 2019-03-01 |
| Animal-Assisted Interactions in Children With Life-Threatening Conditions and Their Parents (NCT03765099) | Vanderbilt-Ingram Cancer Center | 2019-02-21 |
| A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancer (NCT03425565) | University College, London | 2019-02-18 |
| A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies (NCT03829501) | Kymab Limited | 2019-01-28 |
| Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 (NCT03785249) | Mirati Therapeutics Inc. | 2019-01-15 |
| Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors (NCT03810339) | Sun Yat-sen University | 2019-01-15 |
| DM-CHOC-PEN for Brain Tumors in AYA Subjects (NCT03668847) | DEKK-TEC, Inc. | 2019-01-01 |
| A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors (NCT03792750) | Bristol-Myers Squibb | 2018-12-31 |
| Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (NCT03714958) | Centre Leon Berard | 2018-12-20 |
| MGD019 DART® Protein in Unresectable/Metastatic Cancer (NCT03761017) | MacroGenics | 2018-12-12 |
| Feasibility, Acceptability and Preliminary Effects of the Spiritual Care Assessment and Intervention (NCT03823313) | Indiana University | 2018-12-10 |
| Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy (NCT03811379) | Sun Yat-sen University | 2018-11-21 |
| Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies (NCT03722186) | Jiangsu HengRui Medicine Co., Ltd. | 2018-11-13 |
| POEM (Practice of Embracing Each Moment) Study (Delivery Science) (NCT03751995) | Kaiser Permanente | 2018-10-31 |
| Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma (NCT03717298) | Catalysis SL | 2018-10-30 |
| A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma (NCT03730142) | Shanghai Jiatan Pharmatech Co., Ltd | 2018-10-25 |
| Early Palliative Care on Quality of Life of Patients With Advanced Pancreas Cancer (NCT03837132) | University of Manitoba | 2018-10-15 |
| Validation Studies of Biomarkers for Precision Radiation Oncology in Locally Advanced Solid Tumors (NCT04110223) | Shandong Cancer Hospital and Institute | 2018-10-08 |
| Extra Layer Of Support (NCT03532997) | Duke University | 2018-10-01 |
| Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab (NCT03674567) | RAPT Therapeutics, Inc. | 2018-09-25 |
| Personalized Vaccine Generated by Autologous Dendritic Cells Pulsed With Autologous Whole Tumor Cell Lysate Treat Advanced Solid Tumor Patients With High Tumor Mutation Burden (NCT03671720) | Capital Medical University | 2018-09-11 |
| An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors (NCT03661632) | Bristol-Myers Squibb | 2018-09-11 |
| COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (NCT03667716) | Compugen Ltd | 2018-09-06 |
| A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy (NCT03391479) | University Health Network, Toronto | 2018-08-15 |
| Patient-centered Self-administered Acupressure for Fatigue Management in Chinese Advanced Cancer Patients (NCT03610243) | The University of Hong Kong | 2018-08-07 |
| Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain (NCT03605771) | Grupo Español Multidisciplinar de Melanoma | 2018-08-07 |
| Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells (NCT03554889) | Hangzhou Cancer Hospital | 2018-08-01 |
| Uncertainty in Illness in Palliative Care: an Intervention for Family Caregivers (NCT03518970) | Universidad Nacional de Colombia | 2018-08-01 |
| Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers (NCT03568058) | Aaron Miller | 2018-07-26 |
| A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML (NCT03690154) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | 2018-07-23 |
| Stress Management and Resilience Training (SMART) Intervention for Family Caregivers of Individuals With Advanced Cancer (NCT03565757) | Mayo Clinic | 2018-07-19 |
| Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma (NCT03526679) | National Taiwan University Hospital | 2018-07-12 |
| CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma (NCT03582618) | TaiRx, Inc. | 2018-07-12 |
| Oral AMXT 1501 Dicaprate in Combination With DFMO (NCT03536728) | Aminex Therapeutics, Inc. | 2018-06-12 |
| 3D Prediction of Patient-Specific Response (NCT03561207) | KIYATEC | 2018-06-11 |
| An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (NCT03459222) | Bristol-Myers Squibb | 2018-05-30 |
| Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors (NCT03510104) | Meryx, Inc. | 2018-05-22 |
| A Study of CS1003 in Subjects With Advanced Solid Tumors (NCT03475251) | CStone Pharmaceuticals | 2018-05-09 |
| An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (NCT03335540) | Bristol-Myers Squibb | 2018-05-07 |
| Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. (NCT03525392) | Ipsen | 2018-05-03 |
| A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies (NCT03440437) | invoX Pharma Limited | 2018-04-16 |
| AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors (NCT03579628) | Valerio Therapeutics | 2018-04-05 |
| An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed (NCT03444753) | Bristol-Myers Squibb | 2018-04-05 |
| Survival Expectations and Hope Among Cancer Patients at End-of-Life (NCT03325218) | Duke-NUS Graduate Medical School | 2018-04-01 |
| Emergency Medicine Palliative Care Access (NCT03325985) | NYU Langone Health | 2018-03-28 |
| Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia (NCT03254173) | Catherine Naseef Hunter | 2018-03-26 |
| An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (NCT03446040) | Bristol-Myers Squibb | 2018-03-08 |
| The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients (NCT04303091) | Dr. Nicole Culos-Reed | 2018-03-02 |
| Molecular Tumor Board at the Center for Personalized Medicine Tübingen (NCT03503149) | University Hospital Tuebingen | 2018-03-01 |
| The PediQUEST Response Intervention Study (NCT03408314) | Joanne Wolfe, MD, MPH | 2018-03-01 |
| RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions. (NCT03375437) | Centre Leon Berard | 2018-02-15 |
| Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer (NCT03029403) | University Health Network, Toronto | 2018-02-12 |
| Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (NCT03356223) | Centre Leon Berard | 2018-02-05 |
| Exercise and Nutritional Rehabilitation in Patients With Cancer (NCT03316157) | University of Edinburgh | 2018-01-30 |
| Psychosocial Intervention in Latino Patients with Advanced Cancer (NCT03763032) | University of Colorado, Denver | 2018-01-23 |
| Telephone-Based Mindfulness CBT for Patients in Community Settings With Advanced Cancer (NCT03285633) | Duke University | 2018-01-03 |
| Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors (NCT03352531) | Akesobio Australia Pty Ltd | 2018-01-02 |
| Celiac Plexus Radio-Surgery for Pain Management (NCT03323489) | Dr. Yaacov Lawrence | 2018-01-01 |
| A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer (NCT03507166) | RemeGen Co., Ltd. | 2017-12-28 |
| A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors (NCT03369223) | Bristol-Myers Squibb | 2017-12-06 |
| The "Hand-in-Hand Study": Improvement of Quality of Life in Palliative Cancer Patients Through Collaborative Advance Care Planning (NCT03387436) | PD. Dr. med. Carola Seifart | 2017-12-04 |
| Pain Coping Skills and Meaning-Centered Intervention (NCT03207360) | Duke University | 2017-11-17 |
| Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers (NCT03195699) | Tvardi Therapeutics, Incorporated | 2017-11-15 |
| A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors (NCT03312842) | CStone Pharmaceuticals | 2017-10-19 |
| Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (NCT03307785) | Tesaro, Inc. | 2017-10-12 |
| A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors (NCT03129139) | Minneamrita Therapeutics LLC | 2017-10-10 |
| Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors (NCT03261011) | Akesobio Australia Pty Ltd | 2017-10-03 |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (NCT03175224) | Apollomics Inc. | 2017-09-27 |
| Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC (NCT03177291) | H. Lee Moffitt Cancer Center and Research Institute | 2017-09-26 |
| A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics (NCT02944864) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-09-13 |
| Randomized Controlled Trial of Integrated Early Palliative Care (NCT03181854) | Seoul National University Hospital | 2017-09-08 |
| PEN-866 in Patients With Advanced Solid Malignancies (NCT03221400) | Tarveda Therapeutics | 2017-08-29 |
| Efficacy of Self-education Program for Advanced Care Planning(RCT) (NCT03252678) | Seoul National University Hospital | 2017-08-17 |
| Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors (NCT03243643) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2017-08-08 |
| A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers (NCT02919696) | Eli Lilly and Company | 2017-08-07 |
| A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics (NCT03099330) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2017-07-19 |